Echosens is Introducing FibroScan 630 Expert, an Innovative Device for Non-invasive Liver Diagnosis

Food and Healthcare Press Releases Wednesday April 11, 2018 12:00
PARIS--11 Apr--PRNewswire/InfoQuest
Echosens, the company behind the industry-leading FibroScan technology, is introducing FibroScan 630 Expert, a unique device that drives non-invasive liver disease management to the next level.
(Photo: https://mma.prnewswire.com/media/664142/Echosens_FibroScan_630_Expert.jpg )
(Logo: https://mma.prnewswire.com/media/664145/Echosens_Logo.jpg )

Chronic liver disease represents a major and rising public healthcare issue, affecting more than one billion people worldwide. It can be caused by a virus, such as hepatitis B or C, by excessive alcohol consumption or by dietary habits, resulting in conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). These diseases generally remain symptomless and undetected until their very late stages but they progressively worsen over time and might ultimately lead to life-threatening complications, such as liver cirrhosis and liver cancer.

FibroScan is an accurate and efficient solution that quantifies liver fibrosis and steatosis non-invasively in just a few minutes bringing extra clinical confidence to support the management of patients with chronic liver diseases, thus avoiding painful liver biopsies. FibroScan relies on proprietary technology "Vibration-Controlled Transient Elastography", or VCTE, which relies on the combination of shear waves and ultrasound generated at the tip of the device's probe.

The new flagship FibroScan enhances the exam's efficiency, extends the patient's applicability and expands clinical capabilities.

FibroScan 630 Expert features a high performance elastography engine, improved ergonomics, embedded ultrasound guidance system, spleen-dedicated exam, intuitive user interface, touchscreen and advanced keyboard, as well as an integrated barcode reader.

The new device will be launched at the International Liver Congress 2018 that takes place from April 11 to April 15, 2018 in Paris.
About Echosens

Echosens is an innovative high-technology company based in France. Since its inception in 2001, Echosens has been recognized as the world's leading provider of non-invasive diagnostic devices for patients with chronic liver diseases. Innovative non-invasive technologies by Echosens are recognized for cost effectively diagnosing and monitoring chronic liver diseases with precision, standardization and repeatability over time and users. The Group develops, manufactures and sells under its own names and trademarks duly registered portfolio of products and solutions to physicians for the diagnosis, assessment and monitoring of various chronic liver diseases. Liver diseases, being a major rising public health issue, represent a main development focus for Echosens.

Contact:
Echosens
communication@echosens.com
+33-1-44-82-78-50
Source: Echosens

Latest Press Release

Walgreens Boots Alliance and Microsoft establish strategic partnership to transform health care delivery

- Companies aim to improve health outcomes and lower overall costs with enhanced digital and retail experiences and an R&D commitment to build health care solutions through seven-year agreement Walgreens Boots Alliance Inc. (WBA) and Microsoft Corp....

Ascensia Diabetes Care Announces Global Partnership With POCTech to Distribute and Co-develop Continuous Glucose Monitoring Systems

Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems. (Logo:...

MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7

MGI, established in 2016 as a subsidiary of global genomics leader BGI Group, announced it has reached a new milestone of 1,000 MGI sequencers installed in 16 countries. MGI Chief Operating Officer Dr. Hui Jiang also announced the availability of MGI's...

Gift of Life Donor Program is U.S. Leader in Saving Lives

For the 11th consecutive year, Gift of Life Donor Program is the nation's leading organ procurement organization (OPO), coordinating the most life-saving organs for transplant among all 58 U.S. OPOs. Gift of Life broke two national records in 2018,...

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

Licensing rights are worldwide excluding US, Canada, Japan and South AmericaHelsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Menarini, an Italian biopharmaceutical Group active in 136 countries worldwide, today...

Related Topics